AprilBio FY 2025 Annual ReportBeta
AprilBio annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 13, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
AprilBio FY 2025 Annual Report Analysis
Business Overview
- • 100% revenue from license-out of novel antibody and sustained-recombinant protein drug candidates in FY2025, including USD 475M deal with Evommune in June 2024
- • APB-R3 IL-18 binding fusion protein licensed to Evommune (6/20/2024), clinical 2a stage ongoing for atopic dermatitis since Feb 2025
Management Discussion & Analysis
- • Revenue KRW 2.172B (-92.11% YoY), operating loss KRW 7.264B vs prior operating profit KRW 16.87B, net loss KRW 9.728B vs prior net income KRW 20.01B
- • SAFA platform-driven pipeline with APB-A1 and APB-R3 licensing deals totaling over USD 892M, enabling first profitability post-IPO
Risk Factors
- • USD 21.33M foreign currency net asset exposure, KRW 30.61B equivalent at fiscal year-end 2025
- • USD 1,333,158 cash and cash equivalents valued at KRW 1.91B, and USD 20M short-term financial products at KRW 28.7B at fiscal year-end 2025
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding